Veradermics MANE
NYSE MANE
$98.31 +0.56 (+0.57%)
As of: Sep 4, 2026 · 3:59 PM EDT

Veradermics (MANE) Change in Accured Expenses (2025 - 2026)

Veradermics' (MANE) quarterly Change in Accured Expenses came in at -$1.4 million in Q1 2026, down 59.28% YoY from -$3.4 million in Q1 2025, and down 59.28% on a QoQ basis from -$862000.0 in Q1 2025.

Analysis

Veradermics (MANE) Change in Accured Expenses (2025 - 2026) Analysis & Trends

Veradermics (MANE) has 2 years of Change in Accured Expenses data on file, last reported at -$1.4 million in Q1 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 11.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 55.78 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 212.44 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 61.62 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 68.82 Mn
10 Veradermics 3.96 Bn 3.96 Bn - -211,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -211,000.00
Mar 31, 2026 -1.37 Mn
Jun 30, 2025 1.56 Mn
Mar 31, 2025 -862,000.00